激光与假照射治疗绝经泌尿生殖综合征的随机对照试验
在比利时一家三级中心开展的単中心、假照射对照、双盲随机试验纳入60名中重度绝经泌尿生殖综合征女性,所有参与者先后接受三次激光和三次假照射。激光组最困扰症状严重度评分从2.86±0.35降至2.17±0.93(-23.60%;95% CI -36.10%至-11.10%),假照射组从2.90±0.31降至2.52±0.78(-13.20%;95% CI -22.70%至-3.73%),组间比较p=0.13。12周时激光治疗反应与假照射相当,次要结局无明显差异,至18个月未报告严重不良事件。
要点
- 激光组最困扰症状严重度评分下降23.60%(95% CI -36.10%至-11.10%),假照射组下降13.20%(95% CI -22.70%至-3.73%),组间p=0.13。
- 12周时激光治疗反应与假照射相当,次要结局无明显差异。
- 至18个月随访未报告严重不良事件。
核心结论
- 在绝经泌尿生殖综合征女性中,激光治疗后12周的治疗反应与假照射相当,次要结局无明显差异,未报告严重不良事件。
研究设计与样本
- 単中心、假照射对照、双盲随机试验,在比利时一家三级中心开展,纳入60名中重度绝经泌尿生殖综合征症状女性。
- 所有参与者最终先后接受三次连续激光和三次连续假照射,顺序为先激光后假照射或反之。
主要发现
- 激光组最困扰症状严重度评分从2.86±0.35降至2.17±0.93(-23.60%;95% CI -36.10%至-11.10%)。
- 假照射组最困扰症状严重度评分从2.90±0.31降至2.52±0.78(-13.20%;95% CI -22.70%至-3.73%)。
- 两组最困扰症状严重度评分变化组间比较p=0.13。
- 至18个月未报告严重不良事件。
关键数值与推荐
- 主要结局为12周时参与者报告的最困扰症状严重度变化。
- 次要结局包括患者满意度、性功能、泌尿功能等主观测量以及pH、阴道健康指数评分、活体显微镜检查等客观测量,评估短期效果及治疗开始后18个月时的疗效持久性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether CO2 laser treatment is more effective than sham application in relieving the most bothersome symptom (MBS) in women with genitourinary syndrome of menopause (GSM). DESIGN: Single-centre, sham-controlled, double-blind, randomised trial. SETTING: A tertiary centre in Belgium. POPULATION: Sixty women with moderate to severe GSM symptoms. METHODS: All participants eventually received three consecutive laser and three consecutive sham applications, either first laser followed by sham, or conversely. MAIN OUTCOME MEASURES: The primary outcome was the participant-reported change in severity of the MBS at 12 weeks. Secondary outcomes included subjective (patient satisfaction, sexual function, urinary function) and objective (pH, Vaginal Health Index Score, in vivo microscopy) measurements assessing the short-term effect and the longevity of treatment effects at 18 months after start of the therapy. Adverse events were reported at every visit. RESULTS: The MBS severity score decreased from 2.86 ± 0.35 to 2.17 ± 0.93 (-23.60%; 95% CI -36.10% to -11.10%) in women treated with laser compared with 2.90 ± 0.31 to 2.52 ± 0.78 (-13.20%; 95% CI -22.70% to -3.73%) in those receiving sham applications (p = 0.13). There were no serious adverse events reported up to 18 months. CONCLUSIONS: In women with GSM, the treatment response 12 weeks after laser application was comparable to that of sham applications. There were no obvious differences for secondary outcomes and no serious adverse events were reported.
引用
- Page AS, Verbakel JY, Verhaeghe J, et al. Laser versus sham for genitourinary syndrome of menopause: A randomised controlled trial. BJOG. 2022. PMID: 36349391. doi:10.1111/1471-0528.17335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。